CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
CBAY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.73%104.101.1%$1332.57m
GILDGilead Sciences, Inc.
0.04%72.440.9%$675.30m
AMGNAmgen Inc.
-0.45%170.001.1%$499.55m
BIIBBiogen Inc.
0.00%313.971.2%$468.09m
REGNRegeneron Pharmaceuticals, Inc.
-0.79%391.592.7%$363.74m
ALXNAlexion Pharmaceuticals, Inc.
0.49%110.871.9%$288.55m
VRTXVertex Pharmaceuticals Incorporated
-0.36%147.411.9%$237.28m
INCYIncyte Corporation
-0.95%105.472.5%$187.59m
ALNYAlnylam Pharmaceuticals, Inc
0.89%127.5110.6%$184.43m
ILMNIllumina, Inc.
0.25%209.023.5%$165.18m
NKTRNektar Therapeutics
0.13%44.996.1%$146.11m
JUNOJuno Therapeutics, Inc.
1.56%58.6413.5%$138.44m
BMRNBioMarin Pharmaceutical Inc.
0.39%82.884.4%$117.68m
SRPTSarepta Therapeutics, Inc.
1.94%56.1116.8%$117.17m
BLUEBluebird Bio, Inc.
1.90%163.2017.2%$116.94m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.